BIA: UK pricing uncertainty causing companies to rethink drug launches
This article was originally published in Scrip
Executive Summary
Continued uncertainty over an overhaul of the UK's pricing and reimbursement regime is making companies rethink their launch sequences for new products and is putting investors off the UK as a top place to conduct clinical development, so says Steve Bates, CEO of BioIndusrtry Association.